MVA-BN-Brachyury IV vaccine / Bavarian Nordic - LARVOL DELTA

Phase 1 open-label trial of intravenous administration of MVA-BN-brachyury-TRICOM vaccine in patients with advanced cancer. (PubMed, J Immunother Cancer) - P1 | "Intravenous administration of MVA-BN-brachyury-TRICOM vaccine was safe and tolerable. Maximum tolerated dose was not reached. The maximum administered dose was 10 infectious units every 3 weeks for three doses. This dose was selected as the recommended phase 2 dose."

Clinical • Journal • P1 data • Chordoma • Hypotension • Infectious Disease • Inflammation • Oncology • Pain • Respiratory Diseases • Sarcoma • Solid Tumor • CD8

[VIRTUAL] A phase 1 open label trial of intravenous administration of MVA-BN-Brachyury vaccine in patients with advanced cancer. (ASCO 2021) - P1 | "MVA-BN-Brachyury IV vaccine is safe across all tested dose levels and suggesting activity in chordoma at DL3 for which this vaccine was granted FDA orphan drug designation . Mild cytokine release syndrome (rigors, chills, fever and hypotension) has been observed in 5 patients and managed with IV fluids and steroids in 2 patients . A dose 1 x 109 Inf.U (DL3) was selected for RP2D based upon available safety data ."

Clinical • P1 data • Chordoma • Colorectal Cancer • Gastrointestinal Cancer • Hypotension • Infectious Disease • Inflammation • Oncology • Pain • Solid Tumor • CD8 • MUC1

A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer (clinicaltrials.gov) - P1; N=13; Completed; Sponsor: Bavarian Nordic; Active, not recruiting ➔ Completed

Clinical • Trial completion • Breast Cancer • HER2 Breast Cancer • Hormone Receptor Breast Cancer • Lung Cancer • Non Small Cell Lung Cancer • Oncology • ALK • BRAF • EGFR • ER • PGR